In Silico and In Vitro Identification of New Eugenol Derivatives as Inhibitors of the Spike SARS ‐ CoV ‐2 Protein Interaction With the ACE2 Host Receptor
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70212 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2025. Written by Timoteo Delgado-Maldonado and 6 co-authors. Institution: Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, México. Major MEDLINE topics: Angiotensin-Converting Enzyme 2, Eugenol, Spike Glycoprotein, Coronavirus, Antiviral Agents. 50 references. Funded by: Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional.
Abstract (original language)
Coronavirus Disease‐2019 (COVID‐19) caused by SARS‐CoV‐2 remains a serious health concern worldwide. Inhibitors of the protein–protein interaction (iPPI) between the SARS‐CoV‐2 spike protein (S) and human Angiotensin‐Converting Enzyme‐2 (ACE2) are promising as potential antiviral agents. This study aimed to identify and evaluate novel compounds as inhibitors of the S receptor‐binding domain (RBD) and ACE2 interaction through Eugenol‐ and Structure‐Based virtual screening approaches. The hit compounds were corroborated as protein–protein interaction inhibitors using an ELISA‐based enzyme assay. Molecular docking and molecular dynamics (MD) studies of the selected compounds showed that they maintained a molecular interaction and stability (RMSD fluctuations less than 4 Å) with essential residues of the S protein. The best compound, Eu‐1 (IC 50 = 16 μM), prevented the interaction between the S protein and ACE2 receptor efficiently with an 83.7% inhibition at 50 μM. In addition, Eu‐1 had an adequate value of cytotoxicity (CC 50 > 200 μM). Therefore, Eu‐1 is a candidate compound for further SARS‐CoV‐2 preclinical experiments.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, México.
- Laboratorio de Estudios Epidemiológicos, Clínicos, Diseños Experimentales e Investigación, Facultad de Ciencias Químicas, Universidad Autónoma "Benito Juárez" de Oaxaca, Avenida Universidad S/N, Ex Hacienda Cinco Señore…
- Instituto de Biotecnología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, México.
- School of Integrative Biological and Chemical Sciences (SIBCS) & School of Earth, Environmental, and Marine Sciences (SEEMS), University of Texas Rio Grande Valley, Edinburg, Texas, USA.
ORCID profiles: Timoteo Delgado-Maldonado, Alonzo González-González, Adriana Moreno-Rodríguez, Guadalupe Rojas-Verde, Alma D Paz-Gonzalez, Debasish Bandyopadhyay, Gildardo Rivera
Funding
- Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional
Cite
APA
Delgado-Maldonado, T., González-González, A., Moreno-Rodríguez, A., Rojas-Verde, G., Paz-Gonzalez, A. D., Bandyopadhyay, D., & Rivera, G. (2025). In Silico and In Vitro Identification of New Eugenol Derivatives as Inhibitors of the Spike SARS ‐ CoV ‐2 Protein Interaction With the ACE2 Host Receptor. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70212
Vancouver
Delgado-Maldonado T, González-González A, Moreno-Rodríguez A, Rojas-Verde G, Paz-Gonzalez AD, Bandyopadhyay D, et al. In Silico and In Vitro Identification of New Eugenol Derivatives as Inhibitors of the Spike SARS ‐ CoV ‐2 Protein Interaction With the ACE2 Host Receptor. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70212
BibTeX
@article{DelgadoMaldonado2025,
author = {Delgado-Maldonado, Timoteo and González-González, Alonzo and Moreno-Rodríguez, Adriana and Rojas-Verde, Guadalupe and Paz-Gonzalez, Alma D and Bandyopadhyay, Debasish and Rivera, Gildardo},
title = {In Silico and In Vitro Identification of New Eugenol Derivatives as Inhibitors of the Spike SARS ‐ CoV ‐2 Protein Interaction With the ACE2 Host Receptor},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70212}
}
EUVIMED